Clinical Trial Performance

Since 2025, Tekton-supported studies contributed to 12 FDA product approvals.

Since 2006, Tekton has supported more than 900 clinical trials, including studies that contributed to 100+ FDA product approvals. Tekton combines practicing-physician access with centralized startup, regulatory, recruitment, and site operations, driving performance you can plan around.

Fast Startup

Forward Arrows

3x faster to FPI

Tekton averages six days from site activation to first participant in (FPI) across all studies, compared with a 20-day U.S. site median from activation to first screening.

Centralized feasibility, startup, regulatory, and site operations keep teams aligned and bring continuity to the way your team manages studies.

Predictable Enrollment

Bar Chart

116% avgerage enrollment

Across completed studies, Tekton sites enroll an average of 116% of their initial targets, compared with a current U.S. site median of 80%.

Practicing-physician access, centralized recruitment, and accountable site execution help sites reach their goals early and, when approved, continue enrolling beyond them.

Remarkable Retention

Quality Shield

95% average retention

Across completed studies, Tekton retains an average of 95% of enrolled participants. Consistent site support and trusted physician relationships help participants remain engaged through study completion.

For context, a Tufts Center for the Study of Drug Development analysis reported a 19.1% average dropout rate across global late-development studies (equivalent to 80.9% retention).

Proven Execution

Ops Gears

900+ trials supported

Through two decades, Tekton has supported more than 900 clinical trials across a wide range of therapeutic areas and study designs.

That experience supports consistent feasibility, startup, recruitment, and site execution across the organization.

Tested.
Trusted.
Tekton.

+
trials since 2006
%
avg. enrollment vs. initial goal
+
participants enrolled
%
avg. retention across all studies
+
database patients
+
FDA-approved products supported

Recent Case Studies

Case Study

Phase 3 Flu Vaccine Program

Tekton coordinated startup and recruitment across seven sites in three states for this vaccine program, which encompassed several studies. The program culminated in FDA product approval.

  • All 7 Tekton sites exceeded their initial enrollment goals
  • 169% of the combined initial enrollment goal was achieved
  • 1,500+ participants randomized across the program
  • 340+ participants randomized at the Austin site

Case Study

Type 1 Diabetes Trial

Across three Texas sites, Tekton used physician-led database review and detailed prescreening to focus outreach on likely-qualified participants.

  • All Tekton sites exceeded their initial enrollment goals
  • 170% average enrollment across 3 sites
  • 1-day average regulatory turnaround across sites
  • McKinney reached more than 200% of its initial goal and moved from activation to FPV in 4 days

Case Study

Phase 3 GLP-1 Study

Lacy Anderson, MD, led this Phase 3 GLP-1 study at Tekton’s Moore, OK, site.

  • 1-day regulatory receipt-to-submission turnaround
  • First participant visit in under 24 hours after activation
  • Enrollment goal met 3 months early

Case Study

Alzheimer's Disease Trial

Tekton onboarded and supported a new Principal Investigator while also contributing to study design and implementation.

  • First participant randomized in the study
  • 110% of the initial enrollment goal achieved
  • One of the study’s top-enrolling sites

Case Study

CGM Device Study

Tekton’s Wichita, KS, site used personalized outreach to a pre-identified patient pool for this study involving pregnant participants with diabetes.

  • 240% of the initial enrollment goal achieved
  • 100% participant retention
  • 2-day regulatory turnaround

Case Study

Phase 2 Migraine Study

Robert Lockwood, MD, led this Phase 2 migraine study at Tekton’s former Yukon, OK, location, now Oklahoma City.

  • Enrollment goal met ahead of schedule
  • First participant visit within 48 hours of activation
  • 1.5 days from regulatory receipt to submission
  • 100% participant retention and near-perfect eDiary compliance

More Case Studies

Partner With Tekton

Send us a synopsis or your I/E criteria. We'll respond with the Tekton sites and investigators we recommend, as well as site-level enrollment forecasts.

Complete the form on this page or email .

Submit Your Information